Caleb Desrosiers

Caleb DesRosiers is a healthcare executive with roughly 25+ years of experience spanning government, life sciences, law, and advisory. He holds a B.A., a Master of Public Administration (MPA), and a law degree (JD), all from Suffolk University. He began his career in state government working on policy to expand healthcare access and prescription-drug benefits for seniors, then served as a Special Assistant at the Centers for Medicare & Medicaid Services (CMS) in Washington, DC, advising the Offices of Regulatory Affairs and the Administrator on payment policy and shepherding regulatory clearance across HHS, the White House Office of Management and Budget, and the Office of the Federal Register.

He subsequently spent about five years in the life-science industry at Pfizer and Roche, supporting brand teams on cross-functional payment policy, advocacy, managed care, and commercial/market-access initiatives (holding roles reported as Director at Pfizer and Executive Director at Roche). He later moved into healthcare consulting and advisory, founding DorCel Healthcare Consulting and working in leadership roles associated with Entree Health (a CDM/Omnicom group company) and Valuate Health Consultancy (an Omnicom market-access consultancy), where he has been cited as a Senior Principal.

In his most investment-adjacent role, DesRosiers has served as Managing Director of Investment Services at Health Management Associates (HMA), advising institutional investors on transactions across healthcare services, life sciences, and health IT — i.e., buy-side/deal advisory rather than deploying his own angel capital. He has also been an Operating Partner at Shore Capital Partners (a Chicago-based healthcare-focused private-equity firm), with a stated focus area of life-sciences patient services.

He is active as a board member and advisor: he was appointed to the Board of Directors of Daxor Corporation (Nasdaq: DXR) effective January 18, 2022; joined the board of Health Alliance Plan (HAP) of Michigan (part of Henry Ford Health) in 2021; and has served as an advisory-board member for companies including Copilot Provider Support Services and TruLite Health.

• Works primarily as a transaction and market-access advisor to institutional investors (private equity, strategics) in healthcare — his "investing" activity centers on advising on healthcare-services, life-sciences, and health-IT deals rather than a documented personal angel/seed program.
• Sector expertise concentrates on healthcare payment policy, managed care, market access, and regulatory/reimbursement strategy — reflecting his CMS + pharma background.
• Where he has PE affiliation (Shore Capital Partners), the emphasis is life-sciences patient services and healthcare-services roll-ups, a middle-market PE model — not early-stage angel checks.
• No verified public thesis framing him as a seed-stage angel investor, and no verified personal check size or target-company profile; the stub's "Seed Round / Angel Investors" framing is unconfirmed.